Venom neutralization by purified bioactive molecules: Synthetic peptide derivatives of the endogenous PLA2 inhibitory protein PIP (a mini-review)

Toxicon

Volumn 56, Issue 7, 2010, Pages 1275-1283

  Thwin, Maung Maung ^a   Samy, Ramar Perumal ^a   Satyanarayanajois, Seetharama D ^b   Gopalakrishnakone, Ponnampalam ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Antivenom; Metalloproteinase; Neutralization; Peptide inhibitor; Secretory phospholipase A2; Snake venom

Indexed keywords

LEUCYLALANYLISOLEUCYLTYROSYLSERINE; LEUCYLGLYCYLARGINYLVALYLASPARTYLISOLEUCYLHISTIDYLVALYLTRYPTOPHANYLASPARTYLGLYCYLVALYLTYROSYLISOLEUCYLARGINYLGLYCYLARGININE; LEUCYLPROLYLGLYCYLLEUCYLPROLYLLEUCYLSERYLLEUCYLGLUTAMINYLASPARAGINYLGLYCYLLEUCYLTYROSINE; LEUCYLSERYLLEUCYLGLUTAMINYLASPARAGINYLGLYCYLLEUCYLTYROSINE; MATRIX METALLOPROTEINASE; PHENYLALANYLLEUCYLSERYLTYROSYLLYSINE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PROLYLGLYCYLLEUCYLSERYLLEUCYLGLUTAMINYLASPARAGINYLGLYCYLLEUCYLTYROSINE; PYTHON PHOSPHOLIPASE A2 INHIBITOR; SNAKE VENOM ANTISERUM; TRYPTOPHANYLVALYLSERYLTYROSYLTHREONINE; UNCLASSIFIED DRUG; VALYLALANYLPHENYALANYLARGINYLSERINE; VALYLASPARTYLISOLEUCYLHISTIDYLVALYLTRYPTOPHANYLASPARTYLGLYCYLVALINE;

AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; ENVENOMATION; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; INFLAMMATION; MUSCLE INJURY; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; POISONOUS SNAKE; PRIORITY JOURNAL; REVIEW; SNAKEBITE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIVENINS; BOIDAE; ENZYME INHIBITORS; MATRIX METALLOPROTEINASES; MODELS, MOLECULAR; NEUROTOXINS; PEPTIDES; PHOSPHOLIPASES A2; SNAKE VENOMS; SNAKES;

ANIMALIA; FUNGI; MAMMALIA; SERPENTES;

EID: 77957905267     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2009.12.023     Document Type: Review

References (67)

1. Abubakar M.S., Balogun E., Abdurahman E.M., Nok A.J., Shok M., Mohammed A., Garba M. Ethnomedical treatment of poisonous snakebites: plant extract neutralized Naja nigricollis venom. Pharma. Biol. 2006, 44:343-348.
2. Alcaraz M.J., Payá M. Marine sponge metabolites for the control of inflammatory diseases. Curr. Opin. Investig. Drugs 2006, 7:974-979.
3. 2 in brain. FEBS Lett. 2002, 531:12-17.
4. 2 structure/function, mechanism, and signaling. J. Lipid Res. 2009, 50:S237-S242.
5. 2 and a potent peptide inhibitor Phe-Leu-Ser-Tyr-Lys at 1.8 Å resolution. J. Biol. Chem. 2002, 277:41079-41085.
6. 2 and a designed peptide Leu-Ala-Ile-Tyr-Ser. Acta Cryst. 2002, D58:1813-1819.
7. 2 based on native peptide inhibition. J. Biol. Chem. 2001, 276:33156-33164.
8. 2 inhibitor. J. Neurotrauma 2004, 21:1683-1691.
9. 2 at 1.7A resolution. J. Mol. Biol. 1981, 147:97-123.
10. Dos Santos R.M.M., Oliveira L.C., Estevão-Costa M.I., de Lima M.E., Santoro M.M., Fortes-Dias C.L. Inhibition of crotoxin binding to synaptosomes by a receptor-like protein from Crotalus durissus terrificus (the South American rattlesnake). Biochim. Biophys. Acta (BBA) - Biomembranes 2005, 1717:27-33.
11. 2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol. Rev. 2006, 58:591-620.
12. Fernandes C.M., Zamuner S.R., Zuliani J.P., Rucavado A., Gutiérrez J.M., TeixeiraCde F. Inflammatory effects of BaP1 a metalloproteinase isolated from Bothrops asper snake venom: leukocyte recruitment and release of cytokines. Toxicon 2006, 47:549-559.
13. 2 isoforms in the checkpoint control of acute inflammation. Fed. Am. Soc. Exp. Biol. J. 2004, 18:489-498.
14. Gutiérrez J.M., Rucavado A., Chaves F., Díaz C., Escalante T. Experimental pathology of local tissue damage induced by Bothrops asper snake venom. Toxicon 2009, 54:958-975.
15. Howes J.M., Theakston R.D., Laing G.D. Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators. Toxicon 2007, 49:734-739.
16. 2 Enzymes. Structure, Function and Mechanism 1997, 155-183. Chichester: John Wiley & Sons Ltd., Chichester, United Kingdom. R.M. Kini (Ed.).
17. Kini R.M. Proline brackets and identification of potential functional sites in proteins: toxins to therapeutics. Toxicon 1998, 36:1659-1670.
18. Laing G.D., Clissa P.B., Theakston R.D., Moura-da-Silva A.M., Taylor M.J. Inflammatory pathogenesis of snake venom metalloproteinase-induced skin necrosis. Eur. J. Immunol. 2003, 33:3458-3463.
19. Lentz T.L. Differential binding of nicotine and alpha- bungarotoxin to residues 173-204 of the nicotinic acetylcholine receptor alpha 1 subunit. Biochemistry 1995, 34:1316-1322.
20. 2 in reactive astrocytes in response to transient focal cerebral ischemia in the rat brain. J. Neurochem. 2004, 90:637-645.
21. 2 myotoxin inhibitor proteins from snakes, mammals and plants. Toxicon 2003, 42:963-977.
22. Lomonte B., León G., Angulo Y., Rucavado A., Núñez V. Neutralization of Bothrops asper venom by antibodies, natural products and synthetic drugs: contributions to understanding snakebite envenomings and their treatment. Toxicon 2009, 54:1012-1028.
23. Lozzi L., Lelli B., Runci Y., Scali S., Bernini A., Falciani C., Pini A., Niccolai N., Neri P., Bracci L. Rational design and molecular diversity for the construction of anti-α-bungarotoxin antidotes with high affinity and in vivo efficiency. Chem. Biol. 2003, 10:411-417.
24. 2 inhibitors: medicinal chemistry and therapeutic potential. Curr. Top. Med. Chem. 2007, 7:743-756.
25. Marrow K.J. Developing sophisticated protein-based drugs: peptide drugs. Genet. Eng. News 2005, 25:10-12.
26. 2 from rat neuronal cells and its possible function in the regulation of catecholamine secretion. Biochem. J. 1996, 318:701-709.
27. Meier J., White J. Handbook of Clinical Toxicology of Animal Venoms and Poisons 1995, CRC Press, Boca Raton, FL, pp. 752.
28. 2 inhibitors as potential anti-inflammatory agents. Curr. Pharm. Des. 2005, 1:1301-1312.
29. 2 Inactivation. Chembiochem 2007, 8:1585-1591.
30. 2 inhibitors in arachidonic acid pathway mediated inflammation and snake venom toxicity. Curr. Top. Med. Chem. 2007, 7:787-800.
31. Neves-Ferreira A.G.C., Valente R.H., Perales J., Domont G.B. Natural inhibitors: innate immunity to snake venoms. Handbook of Venoms and Toxins of Reptiles 2009, 259-275. CRC Press, Taylor and Francis Group, (chapter 12). S.P. Mackessy (Ed.).
32. Nirthanan S., Charpantier E., Gopalakrishnakone P., Gwee M.C., Khoo H.E., Cheah L.S., Bertrand D., Kini R.M. Candoxin, a novel toxin from Bungarus candidus, is a reversible antagonist of muscle (αβγδ) but a poorly reversible antagonist of neuronal alpha 7 nicotinic acetylcholine receptors. J. Biol. Chem. 2002, 277:17811-17820.
33. 2 inhibitor in a nonvenomous snake. Elaphe Quadrivirgata. Arch. Biochem. Biophys. 2002, 408:124-130.
34. Pachiappan A., Thwin M.M., Manikandan J., Gopalakrishnakone P. Glial inflammation and neurodegeneration induced by candoxin, a novel neurotoxin from Bungarus candidus venom: global gene expression analysis using microarray. Toxicon 2005, 46:883-899.
35. Perales J., Moussatché H., Marangoni S., Oliveira B., Domont G.B. Isolation and partial characterization of an anti-bothropic complex from the serum of South American Didelphidae. Toxicon 1994, 32:1237-1249.
36. Phillips R.E., Theakston R.D.G., Warrell D.A., Galagedera Y., Abeysekera D.T.D.J., Dissanayake P., Hutton R.A., Aloysius D.J. Paralysis, rhabdomyolysis and haemolysis caused by bites of Russell's viper (Vipera russelli pulchella) in Sri Lanka: failure of Haffkine antivenom. Q. J. Med. 1988, 68:691-716.
37. 2 inhibitors. Curr. Top. Med. Chem. 2007, 7:741-742.
38. Rodriguez-Acosta A., Aguilar I., Giron M.E. Antivenom activity of opossum (Didelphis marsupialis) serum fraction. Toxicon 1995, 33:95-98.
39. Sanchez E.E., Rodriguez-Acosta A. Inhibitors of snake venoms and development of new therapeutics. Immunopharmacol. Immunotoxicol. 2008, 30:647-678.
40. 2 superfamily and its group numbering system. Biochim. Biophys. Acta 2006, 1761:1246-1259.
41. Scherf T., Kasher R., Balass M., Fridkin M., Fuchs S., Katchalski-Katzir E. β-hairpin structure in a 13-mer peptide that binds α-bungarotoxin with high affinity and neutralizes its toxicity. Proc. Natl. Acad. Sci. USA 2001, 98:6629-6634.
42. 2. Nat. Struct. Biol. 1995, 2:458-465.
43. 2 in a complex with a transition-state analogue. Science 1990, 250:1563-1566.
44. 2 from inflammatory exudates. Science 1991, 254:1007-1010.
45. 2 inhibitors from the serum of the Japanese rat snake, Elaphe climacophora. Toxicon 2009, 53:685-692.
46. 2 from Naja naja sagittifera (group I) and a designed peptide inhibitor Val-Ala-Phe-Arg-Ser (VAFRS) at 1.9 Å resolution reveals unique features. Biochemistry 2003, 42:11701-11706.
47. 2 with a group II-specific peptide Leu-Ala-Ile-Tyr-Ser at 2.6 Å resolution. J. Drug Target. 2005, 13:367-374.
48. 2 complexed with indomethacin at 1.4 Å resolution reveals the presence of the new common ligand-binding. J. Mol. Recognit. 2009, 22:437-445.
49. Sivaram P. Editorial: are peptide therapeutics the future?. Curr. Pharm. Biotech. 2006, 7:225-227.
50. 2 enzymes: classification and characterization. BBA- Mol. Cell Biol. Lipids 2000, 1488:1-19.
51. Soares A.M., Januario A.H., Lourenco M.V., Pereira A.M.S., Pereira P.S. Neutralizing effects of Brazilian plants against snake venoms. Drugs of the Future 2004, 29:1105-1117.
52. Soares A.M., Ticli F.K., Marcussi S., Lourenço M.V., Januário A.H., Sampaio S.V., Giglio J.R., Lomonte B., Pereira P.S. Medicinal plants with inhibitory properties against snake venoms. Curr. Med. Chem. 2005, 12:2625-2641.
53. Soares A.M., Marcussi S., Fernandes R.S., Menaldo D.L., Costa T.R., Lourenço M.V., Januário A.H., Pereira P.S. Medicinal plant extracts and molecules as the source of new anti-snake venom drugs. Front. Med. Chem. 2009, 4:309-346.
54. 2 inhibitors from endophytic fungus Trichoderma koningii. Toxicon 2008, 51:240-250.
55. 2 in the central nervous system: implications for neurodegenerative diseases. J. Lipid Res. 2004, 45:205-213.
56. 2 inhibition and venom neutralizing potential. Biochemistry 2000, 39:9604-9611.
57. Thwin M.M., Satish R.L., Chan S.T., Gopalakrishnakone P. Functional site of endogenous phospholipase A2 inhibitor from python serum. Eur. J. Biochem 2002, 269:719-727.
58. 2 activity in the normal and kainate injected rat brain, and inhibition by a peptide derived from python serum. Exp. Brain Res. 2003, 150:427-433.
59. 2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study. Arthritis Res. Ther. 2004, 6:R282-R294.
60. 2 with antiinflammatory activity: solution structure and molecular modeling. J. Med. Chem. 2007, 50:5938-5950.
61. 2 inhibitory peptide on IL-1-beta-induced matrix metalloproteinases production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice. Arthritis Res. Ther. 2009, 11:R138-R153.
62. Tomihara Y., Yonaha K., Nozaki M., Yamakawa M., Kamura T., Toyama S. Purification of three antihemorrhagic factors from the serum of a mongoose (Herpestes edwardsii). Toxicon 1987, 25:685-689.
63. 2- n-dodecylphosphorylcholine complex. Proteins: Struct. Fun. Gen. 1994, 19:330-339.
64. 2 by synthetic peptides derived from the primary sequence. J. Biol. Chem. 1996, 271:23992-23998.
65. 2 in a complex with a transition-state analogue. Science 1990, 250:1560-1563.
66. 2 induces neuronal cell death via apoptosis. Mol. Pharmacol. 2002, 61:114-126.
67. 2 and phospholipids in neural membranes in an experimental epilepsy model. Acta Neurol. Scand. 2002, 106:258-262.